The European Medicines Evaluation Agency: open to criticism. Transparency must be coupled with greater rigour.
作者信息
Abbasi K, Herxheimer A
出版信息
BMJ. 1998 Oct 3;317(7163):898. doi: 10.1136/bmj.317.7163.898.
Abstract
摘要
相似文献
1
The European Medicines Evaluation Agency: open to criticism. Transparency must be coupled with greater rigour.
BMJ. 1998 Oct 3;317(7163):898. doi: 10.1136/bmj.317.7163.898.
2
European Medicines Agency--more transparency needed.
Lancet. 2010 May 22;375(9728):1753. doi: 10.1016/S0140-6736(10)60785-4.
3
The European Medicines Evaluation Agency.
BMJ. 1996 Feb 17;312(7028):394. doi: 10.1136/bmj.312.7028.394.
4
For the European Medicines Agency, a decade of challenges.
J Natl Cancer Inst. 2005 Oct 5;97(19):1403-5. doi: 10.1093/jnci/dji355.
5
[European registration of medicines: pros and cons for prescriber and patient].
Ned Tijdschr Geneeskd. 1997 May 24;141(21):1028-33.
6
EMEA (European Medicines Evaluation Agency) and the new pharmaceutical procedures for Europe.
Health Trends. 1994;26(1):10-3.
7
[Biosimilars: regulatory status for approval].
Farm Hosp. 2010 Mar;34 Suppl 1:16-8. doi: 10.1016/S1130-6343(10)70004-0.
8
The first European Union approval of a new medicine to treat cardiovascular diseases in 2023: why is it important to collaborate with the European Medicines Agency?
Eur Heart J. 2024 Jan 1;45(1):7-9. doi: 10.1093/eurheartj/ehad426.
9
European Medicines Agency pledges to publish clinical reports.
BMJ. 2014 Oct 7;349:g6086. doi: 10.1136/bmj.g6086.
10
European Medicines Agency: leave the UK but remain the same.
J R Soc Med. 2016 Sep;109(9):324-5. doi: 10.1177/0141076816663559.
引用本文的文献
1
Best practices in the African Medicines Regulatory Harmonization initiative: Perspectives of regulators and medicines manufacturers.
PLOS Glob Public Health. 2023 Apr 26;3(4):e0001651. doi: 10.1371/journal.pgph.0001651. eCollection 2023.
2
Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature.
Drug Saf. 2017 Jan;40(1):15-36. doi: 10.1007/s40264-016-0466-1.
3
European medicines evaluation agency is ahead of national licensing authorities.
BMJ. 1998 Oct 17;317(7165):1078. doi: 10.1136/bmj.317.7165.1078.
本文引用的文献
1
Statement of the International Working Group on transparency and accountability in drug regulation.
Int J Risk Saf Med. 1996;9(3):211-7. doi: 10.3233/JRS-1996-9312.
2
Secrecy and transparency of medicines licensing in the EU.
Lancet. 1998 Aug 8;352(9126):480-2. doi: 10.1016/S0140-6736(97)11282-X.
3
The future of healthcare systems. Method for rigorously assessing cost effectiveness of new drugs must be set up.
BMJ. 1997 Oct 11;315(7113):953.
4
Riluzole for amyotrophic lateral sclerosis.
Drug Ther Bull. 1997 Feb;35(2):11-2. doi: 10.1136/dtb.1997.35211.
5
The European Medicines Evaluation Agency.
BMJ. 1996 Feb 17;312(7028):394. doi: 10.1136/bmj.312.7028.394.
6
European Medicines Evaluation Agency and the new licensing arrangements.
Drug Ther Bull. 1994 Dec 15;32(12):89-90. doi: 10.1136/dtb.1994.321289.
Zotero 插件